The biomedical industry is underestimated, and the breakthrough of basic research brings great opportunities
With the development of technology, some of the past fantasies are becoming accessible. Gene editing technology that can change human genetic ability is one of them. Zhang Feng, the top biologist of MIT, is the first one to achieve genome editing in mammalian cells using CRISPR gene editing technology. He founded editas in 2013, which went public three years later and has a market value of nearly $2 billion.
"With the breakthrough of basic medical technology, a group of companies around its application will gradually emerge, all of which have investment potential." Said Shen Jieyong, co-founder of crossover hub.
The Sino US cross-border incubator focuses on biomedical and environmental fields, and its scientific advisory team is composed of professors from Harvard, UC Berkeley and Zhejiang University. Through long-term exchanges with these experts who have made outstanding contributions in their respective fields, Shen Jieyong and his partner Chen Jie realized that there are many opportunities in the field of biomedicine after some breakthroughs have been made in basic research.